

Supplemental Data: Synergistic Effects of Fingolimod and anti-PD-1 radioimmunotherapy in an experimental multiple sclerosis model through enhanced lymph node retention and CD8+ T cell depletion

Frank, C.¹, Allen, K.J.H.¹, Dawicki, W.², Levin, M.C.^{3,4,5,6}, Dadachova, E^{1*}.

¹College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada.

²Department of Biochemistry, Microbiology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada

³Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, University of Saskatchewan, Saskatoon, SK, S7K 0M7, Canada

⁴Cameco MS Neuroscience Research Centre, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7K 0M7, Canada


⁵Neurology Division, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0X8, Canada

⁶Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada


*Corresponding Author

ekaterina.dadachova@usask.ca



+13069665163



Supplemental Fig 1. Total A) brain and B) spleen counts of CD3⁺, CD4⁺ T cells and CD8⁺ T cells in MOG³⁵⁻⁵⁵ EAE 7 days post treatment with aPD-1 RIT (n=3/group). Data analyzed via Two-way ANOVA with Tukey's multiple comparisons. C) Ratio of CD4⁺/CD8⁺ T cells within the spinal cord of MOG³⁵⁻⁵⁵ EAE treated mice.



Supplemental Fig 2. Systemic circulation of radiolabeled antibodies in MOG³⁵⁻⁵⁵ EAE mice at 24 and 48 hours post injection. A) ¹¹¹In-αPD-1 circulation ± FTY720. B) ¹¹¹In-control mAb ± FTY720. Data presented on a scaled range of 1.0 to 2.5 SUV/bw.



Supplemental Fig 3. Radiochemical characterization of ^{177}Lu -DOTA- $\alpha\text{PD-1}$ (^{177}Lu - $\alpha\text{PD-1}$) via A) Radio-HPLC and B) Radio-iTLC. All ^{177}Lu and ^{111}In radiolabeling yields of DOTA- $\alpha\text{PD-1}$ exceeded 95% radiochemical purity.